Abstract
Programmed ribosomal frameshifting (PRF) is the controlled slippage of the translating ribosome to an alternative frame. This process is widely employed by human viruses such as HIV and SARS coronavirus and is critical for their replication. Here, we developed a high-throughput approach to assess the frameshifting potential of a sequence. We designed and tested >12,000 sequences based on 15 viral and human PRF events, allowing us to systematically dissect the rules governing ribosomal frameshifting and discover novel regulatory inputs based on amino acid properties and tRNA availability. We assessed the natural variation in HIV gag-pol frameshifting rates by testing >500 clinical isolates and identified subtype-specific differences and associations between viral load in patients and the optimality of PRF rates. We devised computational models that accurately predict frameshifting potential and frameshifting rates, including subtle differences between HIV isolates. This approach can contribute to the development of antiviral agents targeting PRF.
Introduction
In the standard central dogma, ribosomes translate mRNA by reading codons in a strict three-letter sequence. However, many viruses and certain human genes utilize Programmed Ribosomal Frameshifting (PRF), a mechanism where the ribosome shifts its reading frame by one nucleotide. This "controlled glitch" allows a single mRNA to encode multiple proteins. For instance, HIV relies on PRF to maintain a precise ratio of structural (Gag) to enzymatic (Pol) proteins. Despite its biological significance, understanding the factors that fine-tune PRF rates has been hindered by the low-throughput nature of traditional experiments.
Experimental Design and Methods
To overcome previous limitations, we developed a Massively Parallel Reporter Assay (MPRA) to systematically measure PRF at scale.
The reporter system utilizes a dual-fluorescence construct where mCherry is followed by a variable test sequence and then GFP. The GFP is intentionally placed out-of-frame. Normal translation produces only mCherry, while a frameshift event at the test sequence results in GFP production. The library was integrated into human K562 cells, which were then sorted into 16 bins based on their GFP/mCherry ratio using Flow Cytometry (FACS). Subsequent DNA sequencing of these bins allowed for the reconstruction of frameshifting efficiency for every variant.
Library Composition and Systematic Dissection
The study utilized a comprehensive library of 13,390 oligonucleotides designed to probe the mechanics of PRF.
This library included 12,809 systematic variations of 15 known PRF events (e.g., SARS-CoV, HIV, West Nile virus, and human genes like OAZ1 and PEG10) and 581 sequences from HIV clinical isolates sourced from the Los Alamos National Laboratory (LANL) database.
Key Insights and Results
Our high-throughput analysis revealed several novel regulatory inputs:
- tRNA Availability: We observed a strong negative correlation between tRNA availability (tAI) and frameshifting. Ribosomal pausing at codons with scarce tRNAs increases the probability of a frame slip.
- Nascent Peptide Influence: The specific amino acids added to the growing chain immediately upstream of the slip site influence the rate; charged amino acids, for example, significantly reduce frameshifting.
- HIV Subtype Variation: Subtype C (prevalent in Africa) exhibited significantly higher frameshifting rates than Subtype B (prevalent in Europe/US). Furthermore, high viral loads in patients were associated with PRF rates that approached an "optimal" efficiency, suggesting evolutionary pressure toward specific replication rates.
Using the XGBoost machine learning algorithm, we developed a model that predicts whether a sequence will frameshift with an ROC AUC of 0.93 and predicts the actual rate with a Pearson correlation of 0.81.
Discussion and Future Directions
While the fluorescent assay provides unprecedented scale, it has a detection threshold of approximately 1.3%, potentially missing very low-level events. Additionally, since PRF is sensitive to the cellular environment (e.g., tRNA pools), results in K562 cells may differ from other tissues or during active infection. Future work will focus on using this platform for high-throughput screening of small molecules that disrupt PRF, offering a potential pathway for a new class of broad-spectrum antivirals.
Summary updated